JPMorgan assumed coverage of Surgery Partners (SGRY) with a Neutral rating and $27 price target The firm views current outpatient environment to be most favorable for companies with lower reimbursement exposure to federal funding.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGRY:
- Surgery Partners President Resigns Effective October 2025
- Surgery Partners Announces Credit Agreement Amendment
- Bank of America Sees 5 Market Drivers in Play — and Suggests 2 Stocks to Buy
- Surgery Partners Appoints New Chairman After Resignation
- Surgery Partners: Strategic Positioning and Financial Performance Drive Buy Rating Amid Macroeconomic Challenges